ylliX - Online Advertising Network
Press Release

Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients

Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Dupixent ® (dupilumab) s ignificantly i mproved i tch and h ives in p atients with c hronic s pontaneous u rticaria, a s tep f orward in d emonstrating the r ole of t ype 2 i nflammation in t hese p atients

...read full article on GlobeNewsWire

ylliX - Online Advertising Network